Versartis Inc. (NASDAQ:VSAR)’s share price traded up 3% during trading on Wednesday . The stock traded as high as $11.64 and last traded at $11.45, with a volume of 50,798 shares traded. The stock had previously closed at $11.12.

Several equities analysts have commented on the stock. Morgan Stanley restated a “hold” rating on shares of Versartis in a research note on Saturday, April 30th. Zacks Investment Research downgraded shares of Versartis from a “hold” rating to a “sell” rating in a research note on Wednesday, May 4th. Canaccord Genuity reiterated a “buy” rating on shares of Versartis in a research note on Tuesday, May 10th. Finally, Northland Securities assumed coverage on shares of Versartis in a research note on Thursday, April 7th. They set an “outperform” rating for the company. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. Versartis has an average rating of “Hold” and a consensus price target of $17.20.

The firm’s 50 day moving average price is $10.81 and its 200 day moving average price is $9.30. The company’s market capitalization is $340.78 million.

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.